Press Releases For all investor or media inquiries, visit https://www.adaptimmune.com/contact. Year All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | May 07, 2019 TCR² Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells Apr 29, 2019 TCR² Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast Apr 01, 2019 TCR² Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Mar 28, 2019 TCR² Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting Mar 26, 2019 TCR² Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer Feb 26, 2019 TCR² Therapeutics Announces Exercise of Over-Allotment Option Feb 13, 2019 TCR² Therapeutics Announces Pricing of Initial Public Offering of Common Stock Feb 01, 2019 TCR² Therapeutics Launches Proposed Initial Public Offering Pagination First page « first Previous page ‹ previous Page 1 Current page 2